Helped by beneficial currency moves, sales at Danish company Coloplast increased 19% to DKr 1,112 million ($171 million) in the six months to the end of March. At unchanged exchange rates from the previous year, the rise would still have been strong at 14%, due to growth of the core business and the contribution from the acquisition of Amoena. Sales of Amoena were slightly lower than expected in the first six months but the launch of a light-weight breasts prosthesis and an attachable prosthesis promise good sales growth for the rest of the year, the company said.
Coloplast described the performance of the female stress incontinence device, Contrelle Activgard, on the Danish consumer market as disappointing. In...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?